Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1034"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_dose | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:Evidence_value |
"0.0000012"
|
| ?:content |
"route of administration: oral
study duration: "All volunteers received two single oral doses of 12 mg fluphenazine-HCl: Lyorodin (4 mg fluphenazine-HCl tablet, batch No. 120291), Lyogen retard (3 mg fluphenazine-HCl tablet, batch No. 390061); and an intravenous dose of 2.5 mg: Lyogen 5 solution (5 mg fluphenazine-HCl/ampoule, batch No. 488011) after at least 12 h of fasting on three different days. The washout period was between 7 and 14 days. The three doses were administered according to a randomisation table. All volunteers received standard meals 4 and 10 h after administration of the study medication. The total intake of water within the first 10 h post-dose was 1.5L."
population: 14 healthy volunteers (8 male, 6 female); no participants were tested for known CYP450 phenotypes. NOTE: only twelve participants completed the trial
ages: 30.5 (SD:7.2)
C_max @ 12mg fluphenazine EXTENDED RELEASE: 1.2ng/mL
1.2ng/mL X 1g/10^9ng X 1000mL/1L = 0.0000012g/L"
|
| dc:creator | |
| dc:date |
"06/20/2009 11:39:17"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ fluphenazine_maximum_concentration_continuous_value, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1239 }